Aliasger K. Salem

Dr. Aliasger Salem is the Associate Vice President for Research for the University of Iowa, Bighley Chair and Professor of Pharmaceutical Sciences and an elected member of the American Association for Pharmaceutical Scientists (AAPS) Board of Directors. Dr. Salem is Leader of the Experimental Therapeutics Program at the Holden Comprehensive Cancer Center and co-director of the Nanotoxicology core at the Environmental Health Sciences Research Center. He was educated in applied chemistry at Aston University of Science and Technology, Birmingham, UK (BSc 1998; 1st class honors). He received his Ph.D. in Pharmacy at the University of Nottingham, UK in 2002. He then received postdoctoral training at Johns Hopkins School of Medicine until 2004. He is an elected fellow of the AAPS, an elected fellow of the Controlled Release Society (CRS), an elected fellow of the American Association for the Advancement of Science (AAAS) and an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE). His research interests are primarily focused on advanced drug delivery systems. He is the author of over 250 peer-reviewed scholarly publications and has published in journals that include Science Advances, Nature Nanotechnology, Nature Materials, Nature Reviews Urology and Science Translational Medicine. Dr. Salem regularly serves on international and national grant review panels for organizations that include the American Cancer Society, the National Institutes for Health (NIH), and the Department of Defense: Congressionally Directed Medical Research Programs. For example, he is currently a chartered member of the NIH Advancing Therapeutics study section. In 2020, Dr. Salem was awarded the Hancher-Finkbine Medallion and the Leadership in Research Award by the University of Iowa for life-time achievements in drug delivery research over his career to date.